tobramycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	2684	32986-56-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vantobra tobramycin Nebramycin 6 Nebramycin VI tobracin tobradistin tobralex tobramaxin tobramicin tobramycetin tobramycin sulfate nebcin Tobi Podhaler	An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Molecular weight: 467.52 Formula: C18H37N5O9 CLOGP: -3.44 LIPINSKI: 2 HAC: 14 HDO: 10 TPSA: 268.17 ALOGS: -0.94 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vantobra
tobramycin
Nebramycin 6
Nebramycin VI
tobracin
tobradistin
tobralex
tobramaxin
tobramicin
tobramycetin
tobramycin sulfate
nebcin
Tobi Podhaler

An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Molecular weight: 467.52
Formula: C18H37N5O9
CLOGP: -3.44
LIPINSKI: 2
HAC: 14
HDO: 10
TPSA: 268.17
ALOGS: -0.94
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.11	g	Inhal.powder
0.30	g	Inhal.solution
0.24	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	93 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	19.25 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 20, 2011	EMA	MYLAN IRELAND LIMITED
June 11, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	1810.75	14.39	433	17397	8384	63462808
Hospitalisation	560.31	14.39	329	17501	84752	63386440
Cystic fibrosis	383.56	14.39	103	17727	3193	63467999
Pulmonary function test decreased	259.33	14.39	79	17751	3868	63467324
Pseudomonas infection	245.76	14.39	99	17731	11114	63460078
Haemoptysis	191.01	14.39	112	17718	28614	63442578
Acute kidney injury	171.91	14.39	283	17547	263132	63208060
Cough	150.18	14.39	283	17547	292460	63178732
Pneumonia	130.98	14.39	350	17480	456417	63014775
Anti-neutrophil cytoplasmic antibody positive vasculitis	116.64	14.39	40	17790	2859	63468333
Renal tubular necrosis	111.05	14.39	58	17772	11820	63459372
Death	90.56	14.39	270	17560	374111	63097081
Ventilation perfusion mismatch	88.57	14.39	22	17808	496	63470696
Forced expiratory volume decreased	82.45	14.39	36	17794	4932	63466260
Sputum increased	80.10	14.39	29	17801	2430	63468762
Cystic fibrosis respiratory infection suppression	78.59	14.39	18	17812	283	63470909
Corneal perforation	77.51	14.39	20	17810	528	63470664
Bronchiectasis	77.03	14.39	51	17779	16091	63455101
Cystic fibrosis lung	76.02	14.39	15	17815	109	63471083
Ototoxicity	71.62	14.39	23	17807	1339	63469853
Hypopyon	67.22	14.39	19	17811	713	63470479
Proteinuria	66.93	14.39	50	17780	19095	63452097
Aplastic anaemia	65.39	14.39	38	17792	9531	63461661
Disease complication	62.33	14.39	26	17804	3183	63468009
Conjunctival hyperaemia	59.07	14.39	23	17807	2356	63468836
Staphylococcal infection	58.76	14.39	65	17765	41191	63430001
Corneal oedema	57.73	14.39	20	17810	1473	63469719
Bronchospasm	55.70	14.39	43	17787	17237	63453955
Infection	54.99	14.39	165	17665	229008	63242184
Antibiotic level above therapeutic	54.61	14.39	14	17816	360	63470832
Drug resistance	52.90	14.39	47	17783	22886	63448306
Dysphonia	52.82	14.39	66	17764	47548	63423644
Vasculitis	51.59	14.39	42	17788	18167	63453025
Endophthalmitis	49.94	14.39	23	17807	3569	63467623
Lung disorder	48.90	14.39	73	17757	62188	63409004
Tinnitus	48.79	14.39	55	17775	35573	63435619
Pneumonia pseudomonal	47.45	14.39	20	17810	2513	63468679
Systemic lupus erythematosus	46.84	14.39	3	17827	208915	63262277
Lung transplant	46.55	14.39	21	17809	3107	63468085
Drug level increased	45.43	14.39	43	17787	22693	63448499
Corneal infiltrates	45.29	14.39	10	17820	132	63471060
Off label use	44.88	14.39	333	17497	674129	62797063
Dyspnoea	43.71	14.39	326	17504	660987	62810205
Pneumothorax	42.93	14.39	36	17794	16225	63454967
Synovitis	40.98	14.39	3	17827	186915	63284277
Pseudomonas test positive	40.84	14.39	13	17817	735	63470457
Glossodynia	38.84	14.39	3	17827	178873	63292319
Deafness	37.88	14.39	35	17795	17922	63453270
SLE arthritis	37.86	14.39	12	17818	669	63470523
Eye irritation	37.28	14.39	38	17792	21933	63449259
Abdominal discomfort	37.23	14.39	22	17808	320863	63150329
Wound	34.72	14.39	3	17827	163260	63307932
Overlap syndrome	34.63	14.39	12	17818	884	63470308
Aphonia	34.54	14.39	26	17804	10037	63461155
Acute generalised exanthematous pustulosis	34.43	14.39	27	17803	11072	63460120
Chest discomfort	34.08	14.39	87	17743	109882	63361310
Arthropathy	33.57	14.39	12	17818	234780	63236412
Burkholderia cepacia complex infection	33.50	14.39	8	17822	152	63471040
Ulcerative keratitis	33.50	14.39	16	17814	2694	63468498
Productive cough	33.35	14.39	62	17768	63146	63408046
Pain	32.92	14.39	103	17727	740525	62730667
Condition aggravated	32.82	14.39	209	17621	402008	63069184
Swelling	31.76	14.39	19	17811	275359	63195833
Retinopathy of prematurity	31.53	14.39	9	17821	350	63470842
Drug reaction with eosinophilia and systemic symptoms	29.95	14.39	42	17788	33794	63437398
Ocular hyperaemia	29.73	14.39	36	17794	25108	63446084
Infusion related reaction	29.66	14.39	16	17814	245505	63225687
Nephropathy toxic	29.27	14.39	23	17807	9456	63461736
Visual acuity reduced	28.70	14.39	33	17797	21793	63449399
Elbow deformity	28.50	14.39	12	17818	1503	63469689
Stenotrophomonas infection	28.24	14.39	13	17817	2014	63469178
Keratitis fungal	28.09	14.39	7	17823	160	63471032
Sweat test abnormal	28.05	14.39	5	17825	19	63471173
Pathogen resistance	27.62	14.39	19	17811	6379	63464813
Corneal epithelium defect	27.25	14.39	8	17822	344	63470848
Infective exacerbation of bronchiectasis	27.23	14.39	8	17822	345	63470847
Pneumonia staphylococcal	26.55	14.39	14	17816	2906	63468286
Hypoxia	25.91	14.39	54	17776	59738	63411454
Drug ineffective	25.33	14.39	181	17649	1044584	62426608
Corneal neovascularisation	25.28	14.39	6	17824	111	63471081
Therapeutic product effect incomplete	24.77	14.39	3	17827	125053	63346139
Lipogranuloma	24.67	14.39	4	17826	7	63471185
Mobility decreased	23.77	14.39	3	17827	121156	63350036
Sputum discoloured	23.69	14.39	26	17804	16321	63454871
Injection site pain	23.64	14.39	4	17826	129796	63341396
Increased bronchial secretion	23.59	14.39	11	17819	1755	63469437
Peripheral swelling	23.51	14.39	24	17806	265918	63205274
Rhinovirus infection	23.29	14.39	15	17815	4514	63466678
Eyelid oedema	23.22	14.39	21	17809	10458	63460734
Alopecia	23.08	14.39	37	17793	337499	63133693
Vitritis	22.56	14.39	9	17821	983	63470209
Jaw fracture	22.18	14.39	12	17818	2622	63468570
Ocular hypertension	22.06	14.39	9	17821	1041	63470151
Distal intestinal obstruction syndrome	21.74	14.39	7	17823	411	63470781
Corneal opacity	21.38	14.39	8	17822	735	63470457
Respirovirus test positive	20.66	14.39	4	17826	26	63471166
Corneal thinning	20.33	14.39	5	17825	108	63471084
Corneal disorder	20.28	14.39	10	17820	1804	63469388
Product administered to patient of inappropriate age	19.77	14.39	12	17818	3256	63467936
Respiratory tract infection bacterial	19.74	14.39	6	17824	291	63470901
Retinal detachment	19.55	14.39	15	17815	5954	63465238
Pancreatic failure	19.06	14.39	8	17822	995	63470197
Keratitis bacterial	18.87	14.39	4	17826	43	63471149
Therapy cessation	18.79	14.39	32	17798	30425	63440767
Sinonasal papilloma	18.70	14.39	4	17826	45	63471147
Discomfort	18.66	14.39	12	17818	167362	63303830
Foreign body sensation in eyes	18.32	14.39	10	17820	2224	63468968
Bronchopulmonary aspergillosis allergic	18.22	14.39	10	17820	2248	63468944
Anterior chamber fibrin	18.03	14.39	4	17826	54	63471138
Contusion	17.78	14.39	10	17820	150034	63321158
Fall	17.76	14.39	54	17776	392280	63078912
Eye pain	17.59	14.39	33	17797	33821	63437371
Clubbing	17.34	14.39	6	17824	440	63470752
Bronchial disorder	17.12	14.39	8	17822	1282	63469910
Pupillary block	16.71	14.39	3	17827	12	63471180
Respiratory disorder	16.58	14.39	35	17795	39047	63432145
Spirometry abnormal	16.58	14.39	5	17825	236	63470956
Respiration abnormal	16.51	14.39	14	17816	6403	63464789
Aspergilloma	16.24	14.39	5	17825	253	63470939
Overdose	16.23	14.39	6	17824	115072	63356120
Bronchial wall thickening	15.98	14.39	8	17822	1491	63469701
Intentional product use issue	15.92	14.39	8	17822	127884	63343308
Renal failure	15.63	14.39	70	17760	117582	63353610
Lower respiratory tract infection	15.42	14.39	9	17821	132298	63338894
Bartter's syndrome	15.18	14.39	3	17827	22	63471170
Blastomycosis	15.14	14.39	5	17825	318	63470874
Confusional state	15.14	14.39	27	17803	236353	63234839
Intraocular pressure increased	15.10	14.39	13	17817	6065	63465127
Perineal necrosis	14.92	14.39	4	17826	123	63471069
Forced expiratory volume increased	14.84	14.39	3	17827	25	63471167
Central nervous system fungal infection	14.82	14.39	4	17826	126	63471066
Multiple organ dysfunction syndrome	14.65	14.39	42	17788	56710	63414482
Tracheostomy infection	14.54	14.39	3	17827	28	63471164

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	1581.22	16.65	401	14604	6400	34935526
Hospitalisation	444.40	16.65	286	14719	56616	34885310
Cystic fibrosis	279.89	16.65	76	14929	1582	34940344
Pulmonary function test decreased	204.97	16.65	78	14927	4897	34937029
Pseudomonas infection	199.08	16.65	100	14905	12282	34929644
Choroiditis	178.75	16.65	50	14955	1165	34940761
Endophthalmitis	155.38	16.65	58	14947	3450	34938476
Eye pain	144.15	16.65	83	14922	13379	34928547
Intraocular pressure increased	141.10	16.65	61	14944	5322	34936604
Ototoxicity	128.00	16.65	43	14962	1874	34940052
Cough	120.36	16.65	224	14781	149916	34792010
Haemoptysis	118.35	16.65	107	14898	34899	34907027
Visual acuity reduced	110.69	16.65	75	14930	16074	34925852
Pneumonia	109.35	16.65	372	14633	362255	34579671
Condition aggravated	100.70	16.65	241	14764	191955	34749971
Cystic fibrosis respiratory infection suppression	90.35	16.65	21	14984	224	34941702
Infection	90.05	16.65	149	14856	90766	34851160
Uveitis	84.78	16.65	48	14957	7487	34934439
Sputum discoloured	83.16	16.65	48	14957	7764	34934162
Productive cough	80.57	16.65	90	14915	37723	34904203
Forced expiratory volume decreased	76.48	16.65	34	14971	3169	34938757
Sputum increased	69.20	16.65	29	14976	2341	34939585
Renal tubular necrosis	65.25	16.65	54	14951	15626	34926300
Disease complication	65.19	16.65	29	14976	2707	34939219
Painful respiration	64.24	16.65	23	14982	1213	34940713
Aplastic anaemia	61.55	16.65	43	14962	9673	34932253
Pathogen resistance	55.52	16.65	40	14965	9442	34932484
Lung disorder	54.89	16.65	71	14934	34625	34907301
Bronchospasm	53.28	16.65	41	14964	10690	34931236
Lung transplant	53.24	16.65	23	14982	2001	34939925
Chest injury	51.64	16.65	21	14984	1570	34940356
Dyspnoea	49.63	16.65	303	14702	376479	34565447
Walking aid user	47.79	16.65	21	14984	1903	34940023
Drug resistance	47.31	16.65	57	14948	25870	34916056
Retinopathy of prematurity	44.78	16.65	11	14994	151	34941775
Pancreatic failure	42.04	16.65	15	14990	783	34941143
Increased viscosity of bronchial secretion	41.34	16.65	11	14994	211	34941715
Linear IgA disease	41.21	16.65	18	14987	1608	34940318
Product administered to patient of inappropriate age	39.83	16.65	22	14983	3269	34938657
Hypoacusis	38.53	16.65	41	14964	16260	34925666
Cystic fibrosis related diabetes	38.39	16.65	10	14995	176	34941750
Nephropathy toxic	37.71	16.65	36	14969	12552	34929374
Respiratory tract irritation	36.46	16.65	10	14995	216	34941710
Pneumonia pseudomonal	36.24	16.65	22	14983	3900	34938026
Oxygen saturation decreased	35.34	16.65	74	14931	53744	34888182
Infective exacerbation of bronchiectasis	33.88	16.65	11	14994	430	34941496
Toxic epidermal necrolysis	33.76	16.65	44	14961	21602	34920324
Pseudomonas test positive	33.58	16.65	14	14991	1115	34940811
Deafness	33.33	16.65	32	14973	11233	34930693
Distal intestinal obstruction syndrome	31.97	16.65	10	14995	346	34941580
Tinnitus	31.54	16.65	41	14964	20077	34921849
Deafness neurosensory	31.51	16.65	18	14987	2853	34939073
Aphonia	31.37	16.65	19	14986	3354	34938572
Respiratory disorder	31.36	16.65	40	14965	19224	34922702
Bronchiectasis	31.21	16.65	29	14976	9772	34932154
Ill-defined disorder	31.14	16.65	34	14971	13875	34928051
Influenza	31.11	16.65	67	14938	49599	34892327
Vestibular disorder	30.50	16.65	13	14992	1094	34940832
Fall	29.78	16.65	26	14979	202859	34739067
Increased bronchial secretion	29.64	16.65	15	14990	1866	34940060
Somnolence	29.32	16.65	6	14999	111110	34830816
Arthralgia	28.52	16.65	19	14986	170022	34771904
Staphylococcal infection	27.53	16.65	50	14955	32710	34909216
Aortic aneurysm	27.47	16.65	23	14982	6756	34935170
Corneal epithelium defect	27.28	16.65	9	14996	370	34941556
Acute kidney injury	26.98	16.65	223	14782	304765	34637161
Death	26.63	16.65	274	14731	397775	34544151
Rhonchi	26.35	16.65	14	14991	1926	34940000
Cystic fibrosis lung	26.35	16.65	6	14999	58	34941868
Wheezing	26.10	16.65	56	14949	41346	34900580
Oral candidiasis	26.07	16.65	29	14976	12081	34929845
Rash morbilliform	25.19	16.65	16	14989	3071	34938855
Keratitis bacterial	24.87	16.65	6	14999	76	34941850
Product use issue	23.53	16.65	70	14935	63146	34878780
Toxic anterior segment syndrome	23.47	16.65	11	14994	1158	34940768
Rubber sensitivity	22.87	16.65	7	14998	225	34941701
Ulcerative keratitis	22.14	16.65	12	14993	1717	34940209
Chest discomfort	21.85	16.65	62	14943	54468	34887458
Mycobacterium chelonae infection	20.58	16.65	9	14996	806	34941120
Chondritis	20.53	16.65	6	14999	164	34941762
Scleromalacia	19.86	16.65	4	15001	20	34941906
Cronobacter infection	19.86	16.65	4	15001	20	34941906
Necrotising scleritis	19.82	16.65	5	15000	77	34941849
Flavobacterium infection	19.58	16.65	5	15000	81	34941845
Febrile convulsion	19.41	16.65	8	14997	619	34941307
Aspergillus infection	19.24	16.65	25	14980	12229	34929697
Chronic sinusitis	19.07	16.65	12	14993	2267	34939659
Malignant neoplasm progression	19.02	16.65	7	14998	88039	34853887
Feeling cold	18.76	16.65	23	14982	10616	34931310
Neuralgic amyotrophy	18.57	16.65	6	14999	231	34941695
Keratitis	18.39	16.65	10	14995	1441	34940485
Hypotony of eye	18.27	16.65	5	15000	107	34941819
Trichosporon infection	18.19	16.65	8	14997	726	34941200
Lipogranuloma	18.18	16.65	3	15002	3	34941923
Carbon dioxide increased	18.15	16.65	9	14996	1072	34940854
Malaise	18.08	16.65	139	14866	185686	34756240
Nausea	17.98	16.65	80	14925	339828	34602098
Device related thrombosis	17.59	16.65	9	14996	1146	34940780
Cholangitis infective	17.54	16.65	6	14999	276	34941650
Ocular hyperaemia	17.42	16.65	23	14982	11429	34930497
Tracheostomy	17.19	16.65	8	14997	829	34941097
Hypertension	17.13	16.65	20	14985	136423	34805503
Ocular hypertension	17.12	16.65	8	14997	836	34941090
Anaemia	16.94	16.65	48	14957	233287	34708639
Staphylococcal sepsis	16.91	16.65	21	14984	9823	34932103
Keratitis fungal	16.83	16.65	5	15000	145	34941781

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	2553.67	13.59	633	25426	12218	79706111
Hospitalisation	719.04	13.59	423	25636	93813	79624516
Cystic fibrosis	501.46	13.59	136	25923	3744	79714585
Pulmonary function test decreased	351.40	13.59	121	25938	7516	79710813
Pseudomonas infection	277.96	13.59	136	25923	20767	79697562
Haemoptysis	252.59	13.59	181	25878	55818	79662511
Acute kidney injury	190.59	13.59	480	25579	518924	79199405
Renal tubular necrosis	189.44	13.59	112	25947	24927	79693402
Ototoxicity	178.72	13.59	59	26000	3215	79715114
Choroiditis	171.85	13.59	47	26012	1334	79716995
Endophthalmitis	170.64	13.59	68	25991	6360	79711969
Intraocular pressure increased	147.13	13.59	68	25991	9137	79709192
Pneumonia	144.43	13.59	508	25551	659738	79058591
Cough	133.19	13.59	338	25721	366451	79351878
Disease complication	126.79	13.59	51	26008	4886	79713443
Visual acuity reduced	125.40	13.59	92	25967	29377	79688952
Aplastic anaemia	124.82	13.59	76	25983	17829	79700500
Cystic fibrosis respiratory infection suppression	124.79	13.59	29	26030	415	79717914
Forced expiratory volume decreased	122.63	13.59	57	26002	7757	79710572
Sputum increased	119.67	13.59	48	26011	4565	79713764
Eye pain	115.89	13.59	97	25962	37481	79680848
Drug resistance	98.39	13.59	93	25966	42120	79676209
Cystic fibrosis lung	93.92	13.59	19	26040	134	79718195
Corneal perforation	90.46	13.59	25	26034	738	79717591
Death	86.53	13.59	390	25669	566124	79152205
Sputum discoloured	83.84	13.59	64	25995	21679	79696650
Anti-neutrophil cytoplasmic antibody positive vasculitis	83.76	13.59	35	26024	3694	79714635
Condition aggravated	83.36	13.59	354	25705	500770	79217559
Pathogen resistance	82.72	13.59	54	26005	14288	79704041
Ventilation perfusion mismatch	80.65	13.59	22	26037	618	79717711
Pneumonia pseudomonal	74.20	13.59	37	26022	5874	79712455
Lung transplant	73.84	13.59	34	26025	4527	79713802
Uveitis	72.62	13.59	53	26006	16777	79701552
Productive cough	71.59	13.59	114	25945	88217	79630112
Bronchiectasis	71.53	13.59	59	26000	22327	79696002
Ulcerative keratitis	70.88	13.59	31	26028	3658	79714671
Bronchospasm	70.16	13.59	61	25998	24798	79693531
Nephropathy toxic	69.85	13.59	56	26003	20363	79697966
Tinnitus	69.57	13.59	79	25980	44254	79674075
Hypopyon	68.07	13.59	22	26037	1120	79717209
Completed suicide	67.57	13.59	3	26056	245764	79472565
Corneal oedema	63.62	13.59	26	26033	2594	79715735
Staphylococcal infection	61.26	13.59	85	25974	58210	79660119
Drug level increased	61.10	13.59	70	25989	39581	79678748
Conjunctival hyperaemia	56.51	13.59	28	26031	4385	79713944
Antibiotic level above therapeutic	55.54	13.59	17	26042	723	79717606
Corneal infiltrates	55.11	13.59	14	26045	296	79718033
Infective exacerbation of bronchiectasis	54.79	13.59	17	26042	757	79717572
Dyspnoea	48.45	13.59	459	25600	856566	78861763
Fall	48.22	13.59	53	26006	487576	79230753
Aphonia	47.98	13.59	34	26025	10278	79708051
Corneal epithelium defect	47.59	13.59	15	26044	704	79717625
Painful respiration	47.48	13.59	23	26036	3430	79714899
Lung disorder	47.04	13.59	90	25969	80467	79637862
Pancreatic failure	45.93	13.59	18	26041	1610	79716719
Chest injury	45.57	13.59	21	26038	2800	79715529
Keratitis fungal	44.87	13.59	12	26047	312	79718017
Cystic fibrosis related diabetes	44.12	13.59	11	26048	215	79718114
Pseudomonas test positive	43.68	13.59	18	26041	1834	79716495
Ocular hypertension	43.56	13.59	17	26042	1503	79716826
Lipogranuloma	42.98	13.59	7	26052	10	79718319
Product administered to patient of inappropriate age	42.40	13.59	25	26034	5528	79712801
Increased viscosity of bronchial secretion	42.29	13.59	13	26046	561	79717768
Distal intestinal obstruction syndrome	42.22	13.59	14	26045	773	79717556
Linear IgA disease	40.48	13.59	20	26039	3112	79715217
Acute generalised exanthematous pustulosis	40.16	13.59	38	26021	17216	79701113
Therapeutic product effect decreased	39.22	13.59	4	26055	163859	79554470
Hypoacusis	37.89	13.59	48	26011	30102	79688227
Deafness neurosensory	37.42	13.59	25	26034	6873	79711456
Deafness	37.34	13.59	40	26019	20997	79697332
Infection	37.17	13.59	167	25892	241545	79476784
Corneal neovascularisation	37.17	13.59	9	26050	155	79718174
Pneumothorax	37.04	13.59	46	26013	28277	79690052
Increased bronchial secretion	36.45	13.59	19	26040	3308	79715021
Off label use	36.43	13.59	454	25605	906761	78811568
Ocular hyperaemia	35.59	13.59	45	26014	28161	79690168
Corneal opacity	34.96	13.59	13	26046	1007	79717322
Toxic epidermal necrolysis	34.01	13.59	56	26003	44525	79673804
Necrotising scleritis	33.55	13.59	9	26050	237	79718092
Pain	32.16	13.59	120	25939	703682	79014647
Keratitis bacterial	32.01	13.59	8	26051	158	79718171
Stenotrophomonas infection	31.50	13.59	18	26041	3755	79714574
Respiratory disorder	31.10	13.59	54	26005	44802	79673527
Swelling	31.08	13.59	16	26043	216695	79501634
Aortic aneurysm	30.68	13.59	24	26035	8422	79709907
Proteinuria	30.62	13.59	45	26014	32457	79685872
Rhinovirus infection	29.76	13.59	23	26036	7930	79710399
SLE arthritis	29.63	13.59	10	26049	583	79717746
Mobility decreased	29.19	13.59	3	26056	122172	79596157
Injection site pain	29.01	13.59	4	26055	129834	79588495
Systemic lupus erythematosus	28.88	13.59	3	26056	121146	79597183
Vasculitis	28.48	13.59	38	26021	25064	79693265
Scleromalacia	28.26	13.59	6	26053	55	79718274
Forced expiratory volume increased	28.17	13.59	6	26053	56	79718273
Trichosporon infection	27.92	13.59	11	26048	997	79717332
Syncope	27.64	13.59	12	26047	179437	79538892
Somnolence	27.04	13.59	23	26036	238958	79479371
Burkholderia cepacia complex infection	26.85	13.59	8	26051	310	79718019
Vestibular disorder	26.84	13.59	14	26045	2441	79715888
Mycobacterium chelonae infection	26.83	13.59	14	26045	2442	79715887
Bronchopulmonary aspergillosis allergic	26.62	13.59	15	26044	3046	79715283
Chest discomfort	26.39	13.59	102	25957	137942	79580387
Eyelid oedema	26.02	13.59	27	26032	13660	79704669
Arthropathy	25.50	13.59	13	26046	177098	79541231
Toxic anterior segment syndrome	25.28	13.59	14	26045	2750	79715579
Respiratory tract irritation	25.28	13.59	9	26050	616	79717713
Abdominal discomfort	25.02	13.59	27	26032	250700	79467629
Vitritis	24.82	13.59	12	26047	1782	79716547
Dysphonia	24.38	13.59	56	26003	56816	79661513
Overlap syndrome	24.31	13.59	10	26049	1014	79717315
Intentional overdose	24.31	13.59	3	26056	105957	79612372
Keratitis	24.25	13.59	16	26043	4306	79714023
Clubbing	24.10	13.59	9	26050	706	79717623
Hypotony of eye	24.02	13.59	7	26052	251	79718078
Infusion related reaction	23.87	13.59	24	26035	230213	79488116
Pericarditis	23.79	13.59	3	26056	104233	79614096
Oxygen saturation decreased	23.57	13.59	94	25965	128953	79589376
Glossodynia	23.52	13.59	3	26056	103334	79614995
Rash morbilliform	23.48	13.59	18	26041	6132	79712197
Aspergillus infection	23.28	13.59	30	26029	19131	79699198
Multiple organ dysfunction syndrome	23.11	13.59	89	25970	120157	79598172
Eye irritation	22.99	13.59	31	26028	20650	79697679
Wound	22.85	13.59	5	26054	116174	79602155
Rhonchi	22.79	13.59	15	26044	4021	79714308
Malignant neoplasm progression	22.75	13.59	8	26051	135982	79582347
Influenza	22.55	13.59	93	25966	129513	79588816
Pneumonia staphylococcal	22.51	13.59	16	26043	4858	79713471
Overdose	21.74	13.59	17	26042	184189	79534140
Pain in extremity	21.70	13.59	55	26004	364483	79353846
Arthralgia	21.47	13.59	105	25954	571698	79146631
Corneal thinning	21.40	13.59	6	26053	187	79718142
Respiratory distress	21.31	13.59	54	26005	58285	79660044
Walking aid user	21.08	13.59	21	26038	10127	79708202
Cronobacter infection	20.95	13.59	4	26055	20	79718309
Macular oedema	20.85	13.59	16	26043	5458	79712871
Wheezing	20.52	13.59	84	25975	116580	79601749
Bronchial wall thickening	20.45	13.59	12	26047	2629	79715700
Elbow deformity	20.36	13.59	10	26049	1537	79716792
Flavobacterium infection	20.04	13.59	5	26054	98	79718231
Discomfort	19.99	13.59	8	26051	125609	79592720
Gait disturbance	19.98	13.59	23	26036	207483	79510846
Respiration abnormal	19.76	13.59	18	26041	7770	79710559
Hypertension	19.65	13.59	50	26009	330942	79387387
Gastrointestinal haemorrhage	19.59	13.59	12	26047	147707	79570622
Anaemia	19.55	13.59	77	25982	444938	79273391
Therapeutic product effect incomplete	19.50	13.59	11	26048	141634	79576695
Hypoaesthesia	19.39	13.59	18	26041	179334	79538995
Sputum abnormal	19.14	13.59	9	26050	1256	79717073
Drug reaction with eosinophilia and systemic symptoms	18.99	13.59	55	26004	64189	79654140
Neuralgic amyotrophy	18.98	13.59	6	26053	284	79718045
Sweat test abnormal	18.62	13.59	4	26055	39	79718290
Oral candidiasis	18.40	13.59	34	26025	29594	79688735
Haemodialysis	18.34	13.59	26	26033	18142	79700187
Febrile convulsion	18.34	13.59	8	26051	938	79717391
Post procedural complication	18.26	13.59	30	26029	23799	79694530
Sinonasal papilloma	18.18	13.59	4	26055	44	79718285
Erythema of eyelid	18.14	13.59	11	26048	2559	79715770
Underweight	18.04	13.59	8	26051	975	79717354
Restrictive cardiomyopathy	17.85	13.59	8	26051	1000	79717329
Pulmonary haemorrhage	17.81	13.59	23	26036	14694	79703635
Chondritis	17.70	13.59	5	26054	160	79718169
Respiratory tract infection bacterial	17.58	13.59	10	26049	2067	79716262
Fatigue	17.57	13.59	207	25852	929520	78788809
Anterior chamber fibrin	17.38	13.59	5	26054	171	79718158
Stenotrophomonas test positive	17.38	13.59	6	26053	375	79717954
Therapy cessation	17.23	13.59	38	26021	37524	79680805
Muscle spasms	17.22	13.59	19	26040	174711	79543618
Contusion	17.21	13.59	14	26045	148762	79569567
Pyrexia	16.77	13.59	313	25746	678396	79039933
Corneal disorder	16.67	13.59	10	26049	2281	79716048
Surgical procedure repeated	16.59	13.59	7	26052	757	79717572
Staphylococcal sepsis	16.26	13.59	22	26037	14704	79703625
Psoriatic arthropathy	16.08	13.59	3	26056	77996	79640333
Bronchial disorder	15.91	13.59	10	26049	2479	79715850
Vitamin A deficiency	15.51	13.59	4	26055	90	79718239
Blood creatinine increased	15.42	13.59	95	25964	154962	79563367
Alopecia	15.28	13.59	33	26026	231322	79487007
Muscular weakness	15.27	13.59	18	26041	160711	79557618
Intentional product misuse	15.24	13.59	6	26053	95159	79623170
Interstitial lung disease	15.14	13.59	9	26050	112591	79605738
Vitamin E deficiency	15.11	13.59	3	26056	19	79718310
Infectious crystalline keratopathy	14.98	13.59	3	26056	20	79718309
Scedosporium infection	14.94	13.59	8	26051	1470	79716859
Osteoarthritis	14.83	13.59	5	26054	87304	79631025
Dermatitis exfoliative	14.82	13.59	18	26041	10811	79707518
Bacterial infection	14.75	13.59	32	26027	31248	79687081
Loss of consciousness	14.72	13.59	20	26039	167923	79550406
Herpes zoster	14.69	13.59	6	26053	93077	79625252
Bartter's syndrome	14.61	13.59	3	26056	23	79718306
Staphylococcus test positive	14.56	13.59	14	26045	6467	79711862
Carbon dioxide increased	14.32	13.59	9	26050	2231	79716098
Angle closure glaucoma	14.28	13.59	10	26049	2966	79715363
Jaw fracture	14.16	13.59	10	26049	3007	79715322
Injection site erythema	14.14	13.59	4	26055	78193	79640136
Hypoxia	14.13	13.59	69	25990	103174	79615155
Perineal necrosis	14.07	13.59	4	26055	131	79718198
Cholangitis infective	14.02	13.59	6	26053	671	79717658
Confusional state	13.97	13.59	55	26004	317942	79400387
Moaning	13.92	13.59	7	26052	1130	79717199
Osteopenia	13.91	13.59	23	26036	18341	79699988
Vitamin E decreased	13.90	13.59	3	26056	30	79718299
Respirovirus test positive	13.85	13.59	4	26055	139	79718190
Dizziness	13.83	13.59	108	25951	526333	79191996
Conjunctival oedema	13.80	13.59	7	26052	1151	79717178
Cognitive disorder	13.77	13.59	3	26056	69923	79648406
Retinal detachment	13.69	13.59	16	26043	9231	79709098
Suicide attempt	13.66	13.59	5	26054	82927	79635402
Corneal erosion	13.60	13.59	5	26054	375	79717954
Lip haemorrhage	13.60	13.59	7	26052	1187	79717142

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01GB01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides
ATC	S01AA12	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0000946	Aminoglycosides
FDA EPC	N0000175477	Aminoglycoside Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:27026	toxins
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:33282	bactericides

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Pseudomonas	indication	41381004
Punctate keratitis	indication	42513006	DOID:12197
Pneumonia due to Escherichia coli	indication	51530003
Blepharoconjunctivitis	indication	68659002	DOID:2456
Infection due to Escherichia coli	indication	71057007
Bacterial infection due to Serratia	indication	71120004
Rhinoscleroma	indication	72409005	DOID:11336
Perforation of cornea	indication	74895004
Dacryocystitis	indication	85777005	DOID:9938
Corneal abrasion	indication	85848002
Keratoconjunctivitis	indication	88151007	DOID:9368
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Bacterial conjunctivitis	indication	128350005	DOID:9700
Uveitis	indication	128473001	DOID:13141
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial peritonitis	indication	197171003
Sepsis of the newborn	indication	206376005
Neonatal meningitis	indication	276674008
Escherichia coli urinary tract infection	indication	301011002
Meibomianitis	indication	309779001
Bacterial urinary infection	indication	312124009
Infective blepharitis	indication	312219000
Herpes zoster keratitis	indication	397573005
Rosacea	indication	398909004	DOID:8881
Infection due to Staphylococcus aureus	indication	406602003
Anterior uveitis	indication	410692006	DOID:1407
Nosocomial pneumonia	indication	425464007
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Sepsis due to Pseudomonas	indication	448813005
Allergic conjunctivitis	indication	473460002	DOID:11204
Urinary tract infection caused by Klebsiella	indication	369001000119100
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa	indication
Synergy for Neonatal Meningitis	indication
Klebsiella Pneumoniae Peritonitis	indication
Proteus Mirabilis Osteomyelitis	indication
E. Coli Osteomyelitis	indication
Skin and Skin Structure Proteus Infection	indication
Complicated UTI with Pseudomonas Aeruginosa	indication
Gram-Negative Aerobic Bacillary Pneumonia	indication
Klebsiella Pneumoniae Osteomyelitis	indication
Synergy for Staphylococcal Infections	indication
Staphylococcus Aureus Complicated UTI	indication
Complicated Proteus UTI	indication
Citrobacter Complicated UTI	indication
Enterobacter Osteomyelitis	indication
Synergy for P. Aeruginosa Infection in Cystic Fibrosis	indication
E. Coli Peritonitis	indication
Complicated Urinary Tract Infections	indication
Synergy for Bacterial Meningitis	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Enterobacter Pneumonia	indication
Pseudomonas Aeruginosa Osteomyelitis	indication
Serratia Complicated UTI	indication
Providencia Complicated UTI	indication
Pyrexia of unknown origin	off-label use	7520000
Exposure keratoconjunctivitis	off-label use	14366000	DOID:9461
Neuropathic corneal ulcer	off-label use	231901007
Superficial Ocular Infection	off-label use
Ocular hypertension	contraindication	4210003	DOID:9282
Hypocalcemia	contraindication	5291005
Herpes simplex keratitis	contraindication	9389005
Glaucoma	contraindication	23986001	DOID:1686
Herpes simplex dendritic keratitis	contraindication	29943008
Fungal infection of eye	contraindication	31194008
Parkinsonism	contraindication	32798002
Dehydration	contraindication	34095006
Severe myopia	contraindication	34187009
Tuberculosis of eye	contraindication	49107007
Tinnitus	contraindication	60862001
Diabetes mellitus	contraindication	73211009	DOID:9351
Open-angle glaucoma	contraindication	84494001	DOID:1067
Krukenberg spindle	contraindication	85430004
Herpes zoster ophthalmicus	contraindication	87513003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Eye infection	contraindication	128351009
Bacterial infection of eye	contraindication	128984004
Hypomagnesemia	contraindication	190855004
Pregnancy, function	contraindication	289908002
Viral eye infection	contraindication	312132001
Vaccinia keratitis	contraindication	397552005
Pseudomembranous enterocolitis	contraindication	397683000
Vertigo	contraindication	399153001
Infant Botulism	contraindication
Disorder of the 8th Cranial Nerve	contraindication
Tobramycin Toxicity	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.15	acidic
pKa2	13.85	acidic
pKa3	8.34	Basic
pKa4	7.59	Basic
pKa5	6.94	Basic
pKa6	6.81	Basic
pKa7	5.55	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
28MG	TOBI PODHALER	MYLAN SPECIALITY LP	N201688	March 22, 2013	RX	POWDER	INHALATION	11484671	Nov. 7, 2024	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
28MG	TOBI PODHALER	MYLAN SPECIALITY LP	N201688	March 22, 2013	RX	POWDER	INHALATION	8664187	June 20, 2025	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
0.05%;0.3%	TOBRADEX ST	EYEVANCE	N050818	Feb. 13, 2009	RX	SUSPENSION/DROPS	OPHTHALMIC	8101582	Dec. 19, 2027	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
0.05%;0.3%	TOBRADEX ST	EYEVANCE	N050818	Feb. 13, 2009	RX	SUSPENSION/DROPS	OPHTHALMIC	7795316	Aug. 3, 2028	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
28MG	TOBI PODHALER	MYLAN SPECIALITY LP	N201688	March 22, 2013	RX	POWDER	INHALATION	8869794	Sept. 12, 2028	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
28MG	TOBI PODHALER	MYLAN SPECIALITY LP	N201688	March 22, 2013	RX	POWDER	INHALATION	10207066	Nov. 4, 2030	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Taste receptor type 2 member 20	GPCR	P59543	T2R20_HUMAN	AGONIST	EC50	4.29		IUPHAR
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)	Enzyme		O32553_ECOLX		Km	5.82		WOMBAT-PK

External reference:

ID	Source
4018595	VUID
N0000146911	NUI
D00063	KEGG_DRUG
49842-07-1	SECONDARY_CAS_RN
4018595	VANDF
4018596	VANDF
C0040341	UMLSCUI
CHEBI:28864	CHEBI
TOY	PDB_CHEM_ID
CHEMBL1747	ChEMBL_ID
CHEMBL3989564	ChEMBL_ID
CHEMBL1200780	ChEMBL_ID
D014031	MESH_DESCRIPTOR_UI
DB00684	DRUGBANK_ID
10930	IUPHAR_LIGAND_ID
2990	INN_ID
VZ8RRZ51VK	UNII
36294	PUBCHEM_CID
10627	RXNORM
1090	MMSL
182011	MMSL
2138	MMSL
5590	MMSL
5591	MMSL
5606	MMSL
d00069	MMSL
002779	NDDF
002780	NDDF
13188003	SNOMEDCT_US
373548001	SNOMEDCT_US
89695009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tobrex	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0643	SOLUTION/ DROPS	3 mg	OPHTHALMIC	NDA	17 sections
Tobrex	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0643	SOLUTION/ DROPS	3 mg	OPHTHALMIC	NDA	17 sections
TOBREX	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0644	OINTMENT	3 mg	OPHTHALMIC	NDA	16 sections
TOBREX	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0644	OINTMENT	3 mg	OPHTHALMIC	NDA	16 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0065-0647	SUSPENSION/ DROPS	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0065-0647	SUSPENSION/ DROPS	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0065-0648	OINTMENT	3 mg	OPHTHALMIC	NDA	18 sections
TOBI	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0494	SOLUTION	300 mg	ORAL	NDA	30 sections
TOBI	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0494	SOLUTION	300 mg	ORAL	NDA	30 sections
TOBI Podhaler	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0630	CAPSULE	28 mg	ORAL	NDA	29 sections
TOBREX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0813	OINTMENT	3 mg	OPHTHALMIC	NDA	16 sections
TOBREX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0813	OINTMENT	3 mg	OPHTHALMIC	NDA	16 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0876	OINTMENT	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0876	OINTMENT	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0876	OINTMENT	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0953	SUSPENSION/ DROPS	3 mg	OPHTHALMIC	NDA	18 sections
TobraDex	HUMAN PRESCRIPTION DRUG LABEL	2	0078-0953	SUSPENSION/ DROPS	3 mg	OPHTHALMIC	NDA	18 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3750	SOLUTION	300 mg	RESPIRATORY (INHALATION)	ANDA	30 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3750	SOLUTION	300 mg	RESPIRATORY (INHALATION)	ANDA	30 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4085	SOLUTION	300 mg	RESPIRATORY (INHALATION)	ANDA	26 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4085	SOLUTION	300 mg	RESPIRATORY (INHALATION)	ANDA	26 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0404-7196	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	18 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3577	INJECTION, SOLUTION	10 mg	INTRAMUSCULAR	ANDA	18 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3577	INJECTION, SOLUTION	10 mg	INTRAMUSCULAR	ANDA	18 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3578	INJECTION, SOLUTION	40 mg	INTRAMUSCULAR	ANDA	18 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3578	INJECTION, SOLUTION	40 mg	INTRAMUSCULAR	ANDA	18 sections
TOBRAMYCIN AND DEXAMETHASONE	HUMAN PRESCRIPTION DRUG LABEL	2	0574-4031	SUSPENSION/ DROPS	3 mg	OPHTHALMIC	ANDA	18 sections
BETHKIS	HUMAN PRESCRIPTION DRUG LABEL	1	10122-820	SOLUTION	300 mg	RESPIRATORY (INHALATION)	NDA	34 sections
BETHKIS	HUMAN PRESCRIPTION DRUG LABEL	1	10122-820	SOLUTION	300 mg	RESPIRATORY (INHALATION)	NDA	34 sections
Tobramycin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-883	SOLUTION/ DROPS	3 mg	OPHTHALMIC	ANDA	18 sections